ICICI Securities Ltd | Retail Equity Research Revenues de-grew 3% YoY to | 1419 crore (I-direct estimates: | 1434 crore). Revenues in the pharmaceutical business grew 8% YoY to | 807 crore (I-direct estimate: | 795 crore) while life science ingredients (LSI) revenues de-grew 14% YoY to | 613 crore (I-direct estimate: | 620 crore) due to a decline in life science chemicals segment led by lower crude prices and product calibration EBITDA margins increased 207 bps YoY to 24.0% (I-direct estimates:...